{
    "id": "3492794b-0233-92c1-e063-6294a90a185c",
    "indications": "Flucytosine Capsules are indicated only in the treatment of serious infections caused by susceptible strains of\n \n  Candidaand/or\n \n  Cryptococcus.\n\n \n                  \n                     Candida:Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine.\n\n \n                  \n                     Cryptococcus:Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported.\n\n \n                  Flucytosine Capsules should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to Flucytosine Capsules (see\n \n  \n                        MICROBIOLOGY\n                     ).",
    "contraindications": "The usual dosage of Flucytosine Capsules is 50 to 150 mg/kg/day administered in divided doses at 6-hour intervals. Nausea or vomiting may be reduced or avoided if the capsules are given a few at a time over a 15-minute period. If the BUN or the serum creatinine is elevated, or if there are other signs of renal impairment, the initial dose should be at the lower level (see\n \n  \n                        WARNINGS\n                     ).\n\n \n                  Flucytosine Capsules should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to Flucytosine Capsules (see\n \n  \n                        MICROBIOLOGY\n                     ).",
    "warningsAndPrecautions": "Flucytosine Capsules are supplied as 500 mg flucytosine as follows:\n                  Gray and white capsules imprinted with \"ANCOBON® 500 ICN\".\n                  NDC: 72162-1327-01 - 100 Capsules\n                  NDC: 72162-1327-03 - 30 Capsules\n                  Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F).\n                  Repackaged/Relabeled by:\n  \nBryant Ranch Prepack, Inc.\n  \nBurbank, CA 91504",
    "adverseReactions": "Flucytosine Capsules are contraindicated in patients with a known hypersensitivity to the drug.\n                  Flucytosine Capsules are contraindicated in patients with known complete dihydropyrimidine dehydrogenase (DPD) enzyme deficiency (see\n \n  \n                        WARNINGS\n                     ).",
    "ingredients": [
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "LACTOSE, UNSPECIFIED FORM",
            "code": "J2B2A4N98G"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FLUCYTOSINE",
            "code": "D83282DT06"
        }
    ],
    "organization": "Bryant Ranch Prepack",
    "name": "Flucytosine",
    "effectiveTime": "20250507"
}